Improve Patient Access
with Real-World Data

Integrated Claims, Lab, and Market Access Data

In today’s marketplace, manufacturers need more than just coverage data to improve patient access. Real-world data (RWD)—from sources like medical and pharmacy claims, lab tests and results, and EHRs—reveals how patients actually received care.

That’s where we come in. In a first-of-its-kind offering, MMIT integrates all of these RWD sources with payer coverage and clinical pathways data, creating a unified record of the patient journey. We take the burden of analysis off your shoulders, delivering dashboards of bridged data to answer your critical questions.

Learn More


Showcase 1
PlayPlay
Showcase 1
PlayPlay
Patient Journey

Resolve Access Barriers Throughout
the Patient Journey

Our integrated data dashboards let you track a patient cohort from diagnosis to treatment, noting the critical events and triggers along the way—from test results to payer restrictions that impact provider behavior.

science-icon-blue
Science to
Symptoms
prescription-icon-blue
Diagnosis to
Prescription
therapy-icon-blue
Treatment to End
of Therapy
Science to Symptoms

Science to Symptoms

Events Captured at this Stage
  1. Demographic information: age, gender, geographical location, etc.
  2. Comorbidities: what is the health of the patient?
  3. History of visits: is patient routine on check-ups, etc.?
  4. Lab criteria: biomarkers, genetic testing
Insights at this Stage
  1. Prior to patients being diagnosed, what is their overall health? Can this influence treatment decisions?
  2. Develop standard cohort and stratification
  3. History of patient, look-back/look-forward times
  4. Do they have access to care; are there geographic barriers?
Diagnosis to Prescription

Diagnosis to Prescription

Events Captured at this Stage
  1. Time from diagnosis to treatment
  2. Testing — targeted therapy
  3. HCP preference re combination vs. mono therapy
  4. Treatment to label
  5. Health insurance of patient
  6. What is first event (symptoms, prescription, etc.)
Insights at this Stage
  1. Patient referral patterns, present symptoms and treatment (specialist)
  2. Is there a delay from diagnosis to treatment? What causes delay (payer burden, access to care, specialist)?
  3. What is overall treatment rate — what are reasons diagnosed patient is not being treated; unmet need?
Treatment to End of Therapy

Treatment to End of Therapy

Events Captured at this Stage
  1. Number of refills, days of therapy
  2. Change in prior therapy
  3. Follow-up visits
  4. Cost burden
  5. Testing for adverse events
  6. Switches in current therapy
  7. Setting of care: Center of Excellence, academic vs. community site, travel time
Insights at this Stage
  1. Do patients experience adverse events, are drug reductions or holidays used to manage?
  2. Health outcomes: progression free survival, overall survival, event-free survival, goal of treatment (real world evidence vs. clinical trial, etc.)
  3. Medication possession ratio, days covered ratio
  4. Setting of care: does this influence a patient’s overall care and treatment success/goals?
  5. Has cost of care impacted outcomes?
previous arrow
previous arrow
next arrow
next arrow
Patient Journey
Science to Symptoms
Diagnosis to Prescription
Treatment to End of Therapy
previous arrow
next arrow
Slide
An Overview of MMIT's Data Lake
0m+
Patients

from 2017 onwards, representing commercial, Medicaid & Medicare populations.

View 6+ years of longitudinal data with annual addition of 200m+ patients/year.

0m+
HCPs

with more than 6.5m+ affiliations.

Gain insight into 7K+ hospitals, 5,600+ health systems, and 1,500+ ACOs.

0%
Payers

with benefit plan details like PA, step therapy and quantity limit restrictions.

See rebates, coupons, deductibles, co-insurance and full payment amounts.

0b+
Clinical Lab Transactions

covering 210m+ U.S. lives, with 500m+ diagnostic test results/month.

Track 177m+ lab patients with linked claims and view 200m+ test results from inpatient hospitals.

Answer Your Business Questions with Integrated RWD
Claims Data
Claims Data
green-checkmark

How many patients are actively being managed for their disease?

green-checkmark

What are lengths of therapy?

green-checkmark

What HCPs are managing patients and what influences treatment decision?

Lab Data
Lab Data
green-checkmark

How can I identify and stratify patients with the condition my therapy treats?

green-checkmark

What tests are being done at the HCP and institution level to identify patients with the condition?

green-checkmark

How can I target HCPs after they order a test and before they diagnose and prescribe?

Payer Coverage
Payer Coverage
green-checkmark

How are payers making coverage decisions for my brand?

green-checkmark

What hurdles exist at the plan level for patients to be prescribed?

green-checkmark

Even though my therapy is preferred by a payer, is my competitor’s therapy getting more utilization at that payer?

Pathway Data
Pathway Data
green-checkmark

What are the critical pathways at the institution level and how are they driving treatment decisions?

green-checkmark

Where are the advantages/ disadvantages to payer coverage?

Claims Data
Lab Data
Payer Coverage
Pathway Data
previous arrow
next arrow
Pricing
Find the Right Patients at the Right Time

Patients who have been diagnosed with ovarian, fallopian tube or primary peritoneal cancer over a given time period.

green-checkmark

Patients who have successfully completed a frontline platinum-based regimen.

green-checkmark

Patients who are in remission and haven’t moved on to a second therapy.

green-checkmark

Patients in remission who are actively being managed and maintain levels through lab testing (Cancer Antigen / CA 125).

green-checkmark

Eligible patients at Texas Oncology.

~0k
~0k
~0k
0
0
Slide 3
Additional Resources
Infographic
Reliance on Real-World Data Across the Product Life Cycle
Real-world data informs pharma companies’ decision-making across the development lifecycle. In this infographic, see what percentage of manufacturers are using RWD in each phase, and for what purposes.
Infographic
Overcome Unique Access Barriers in Areas of Clinical Advancement
In this infographic, see the roadblocks specific to each therapeutic area, and learn how manufacturers can help patients overcome them.
Webinar Recording and Executive Summary
Overcoming the Chasm Between Payer Policy and Real-Life Practice
Learn how integrated RWD can help pharma companies understand and improve the patient treatment journey.
Feature #10
desktop-data-icon

Patient Access Analytics

This solution combines coverage, claims and pathways data to provide commercial pharma teams with a unique view of payer and prescriber behavior.

target-icon

Lab Data for Commercial Targeting

MMIT’s Lab Data assets and analysis help manufacturers target the right providers and patients at the right time, before a diagnosis or prescribing decision is made.

Make smarter decisions
with MMIT's real-world data and expertise.

Our RWD powered solutions use mastered, linked and tokenized data assets to deliver clear insights across the patient journey.